Primary aldosteronism: Current knowledge and controversies in Conn's syndrome

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 3, 2007, Pages 220-227

  Schirpenbach, Caroline ^b   Reincke, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Ludwig Maximilians University Clinic ^*

Author keywords

Aldosterone; Conn's syndrome; Primary aldosteronism; Renin; Secondary hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; AMILORIDE; CANRENOATE POTASSIUM; DEXAMETHASONE; EPLERENONE; MINERALOCORTICOID; MITOTANE; PLACEBO; SPIRONOLACTONE;

ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENAL TUMOR; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG DOSE TITRATION; FAMILY HISTORY; GYNECOMASTIA; HORMONE DETERMINATION; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; INCIDENTAL FINDING; MASTALGIA; MENSTRUATION DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; SCREENING; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; HUMANS; HYPERALDOSTERONISM; PREVALENCE;

EID: 33847188882     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0430     Document Type: Review

References (81)

1. Vantyghem M et al. (1999) Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 141: 279-285
2. Benchetrit S et al. (2002) Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr Med Assoc J 4: 17-20
3. Rayner B et al. (2000) The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 90: 394-400
4. Brown M et al. (1996) Primary hyperaldosteronism: a missed diagnosis in 'essential hypertensives'? Aust N Z J Med 4: 533-538
5. Reincke M et al. (2003) Normokalemic primary aldosteronism [in German]. Dtsch Ärztebl 100: A184-A190
6. Bernini G et al. (2002) Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 146: 523-529
7. Fardella C et al. (2000) Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85: 1863-1867
8. Lim P et al. (1999) Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353: 40
9. Gordon R et al. (1993) Evidence that primary aldosteronism may not be uncommon - twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20: 296-298
10. Seiler L et al. (2002) Prevalence of primary hyperaldosteronism in a university hypertension outpatient clinic: is it underdiagnosed? Exp Clin Endocrinol Diabetes 110: S84
11. Lim P et al. (2000) High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14: 311-315
12. Loh K et al. (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85: 2854-2859
13. Rossi E et al. (2002) High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15: 896-902
14. Mulatero P et al. (2004) Increased diagnosis of primary aldosteronism including surgically correctable forms in centers from five continents. J Clin Endocrinol Metab 89: 1045-1050
15. Seiler L et al. (2004) Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 150: 329-337
16. Williams J et al. (2006) Prevalence of primary aldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 20: 129-136
17. Kaplan N (2001) Cautions over the current epidemic of primary aldosteronism. Lancet 357: 953-954
18. Conn J and Lawrence H (1956) Primary aldosteronism, a new clinical entity. Ann Intern Med 44: 1-15
19. Rossi GP et al. (1996) Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27: 1039-1045
20. Mosso L et al. (2003) Primary aldosteronism and hypertensive disease. Hypertension 42: 161-165
21. Mulatero P et al. (2004) Genetics of primary aldosteronism. J Hypertens 22: 663-670
22. Fallo F et al. (1998) Zona fasciculata-like histotype and aldosterone response to upright posture are not related in aldosterone-producing adenomas. Exp Clin Endocrinol Diabetes 106: 74-78
23. Fontes R et al. (1991) Reassessment of the predictive value of the postural stimulation test in primary aldosteronism. Am J Hypertens 4: 786-791
24. Irony I et al. (1990) Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 3: 576-582
25. Connell J and Fraser R (2002) Primary aldosteronism. In The Oxford Textbook of Endocrinology and Diabetes, 791-799 (Eds Wass J and Shalet S) Oxford: Oxford University Press
26. Mulatero P et al. (2005) Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metabol 16: 114-119
27. Gordon R et al. (1995) Primary aldosteronism - some genetic, morphological, and biochemical aspects of subtypes. Steroids 60: 35-41
28. Ballantine DM et al. (1994) Renin gene polymorphism associated with aldosterone responsiveness to the renin-angiotensin system in patients with aldosterone-producing adenomas. Clin Exp Pharmacol Physiol 21: 215-218
29. Jackson R et al. (2002) New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 970: 77-88
30. Stewart P (2000) Dexamethasone-suppressible hypertension. Lancet 256: 679-699
31. Lifton R et al. (1992) A chimaeric 11β-hydroxylase/ aldosterone synthase gene causes glucocorticoidremediable aldosteronism and human hypertension. Nature 355: 262-265
32. Freel E et al. (2004) Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab 89: 2628-2633
33. Litchfield W et al. (1998) Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31: 445-450
34. McMahon G and Dluhy R (2004) Glucocorticoid-remediable aldosteronism. Cardiol Rev 12: 44-48
35. Stowasser M and Gordon R (2001) Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78: 215-229
36. Stowasser M and Gordon R (2000) Primary aldosteronism: learning from the study of familial varieties. J Hypertens 18: 1165-1176
37. Wambach G et al. (1986) Sodium loading raises urinary cortisol in man. J Endocrinol Invest 9: 257-259
38. Hiramatsu K et al. (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 141: 1589-1593
39. McKenna T et al. (1991) Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism. J Clin Endocrinol Metab 73: 952-957
40. Schwartz G and Turner S (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51: 386-394
41. Giacchetti G et al. (2006) Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24: 737-745
42. Montori V et al. (2001) Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 76: 877-882
43. Padfield P (2003) Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol 59: 422-426
44. Auchus R (2003) Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr Opin Nephrol Hypertens 12: 153-158
45. Seifarth C et al. (2002) Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 57: 457-465
46. Gallay B et al. (2001) Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37: 699-705
47. Ferrari P et al. (2004) Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 22: 377-381
48. Trenkel S et al. (2002) Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 110: 80-85
49. Perschel F et al. (2004) Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 50: 1650-1655
50. Stowasser M et al. (2001) Diagnosis and management of primary aldosteronism. JRAAS 2: 156-169
51. Kem D et al. (1971) Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 128: 380-386
52. Mulatero P et al. (2006) Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrin Metab 91: 2618-2623
53. Schirpenbach C et al. (2006) Automated chemiluminescence immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 52: 1749-1755
54. Gordon R et al. (1999) A prospective evaluation of definite tests for primary aldosteronism. Abstracts from the Annual Scientific Meeting of the High Blood Pressure Research Council of Australia: 1999 December; Melbourne, Australia. Melbourne: HBP Research Council of Australia
55. Schirpenbach C et al. (2006) Confirmatory testing in normokalaemic primary aldosteronism: the value of saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol 154: 865-873
56. Agharazii M et al. (2001) Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 37: 1440-1443
57. Young W (2002) Primary aldosteronism. Ann N Y Acad Sci 970: 61-76
58. Mantero F et al. (2003) Does dynamic testing have a place in the modern assessment of endocrine hypertension? J Endocrinol Invest 26: 92-98
59. Abdelhamid S et al. (2003) Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens 16: 522-530
60. Holland OB et al. (1984) Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 6: 717-723
61. Litchfield W et al. (1997) Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 82: 3570-3573
62. Lingam R et al. (2003) CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland. AJR Am J Roentgenol 181: 843-849
63. Guest P (2002) Adrenal imaging. In The Oxford Textbook of Endocrinology and Diabetes, 747-756 (Eds Wass J and Shalet S) Oxford: Oxford University Press
64. Lingam R et al. (2004) Diagnostic performance of CT versus MR in detecting aldosterone-producing adenoma in primary hyperaldosteronism (Conn's syndrome). Eur Radiol 14: 1787-1792
65. Young W et al. (2004) Role for adrenal venous sampling in primary aldosteronism. Surgery 136: 1227-1235
66. Rossi G et al. (2001) Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86: 1083-1090
67. Weinberger MH et al. (1979) Primary aldosteronism. Diagnosis, localization, and treatment. Ann Intern Med 90: 386-395
68. Doppman J and Gill J (1996) Hyperaldosteronism: sampling the adrenal veins. Radiology 198: 309-312
69. Sheaves R et al. (1996) Relative value of computed tomography scanning and venous sampling in establishing the cause of primary aldosteronism. Eur J Endocrinol 134: 308-313
70. Phillips J et al. (2000) Predictive value of preoperative tests in discriminating bilateral hyperplasia from an aldosterone-producing adenoma. J Clin Endocrinol Metab 85: 4526-4533
71. Wheeler M and Harris D (2003) Diagnosis and management of primary aldosteronism. World J Surg 27: 627-631
72. Lim P et al. (2001) A review of the medical treatment of primary aldosteronism. J Hypertens 19: 353-361
73. Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709-717
74. Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321
75. Epstein M (2003) Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 18: 1984-1992
76. Lumachi F et al. (2005) Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 71: 864-869
77. Lo C et al. (1996) Primary aldosteronism. Results of surgical treatment. Ann Surg 224: 125-130
78. Meyer A et al. (2005) Long-term follow-up after adrenalectomy for primary aldosteronsim. World J Surg 29: 155-159
79. Luton JP et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195-1201
80. Anonymous (1979) Idiopathic aldosteronism - a diagnostic artifact? Lancet 2(8154): 1221-1222
81. Kaplan NM (2004) The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 22: 863-869